

Impact of Breast Cancer Subtypes and Treatment on Survival: An Analysis Spanning Two Decades

Reina Haque¹, Syed A. Ahmed¹, Galina Inzhakova¹, Jiaxiao Shi¹, Chantal Avila¹, Jonathan Polikoff¹, Leslie Bernstein², Shelley M. Enger¹, and Michael F. Press³

Abstract

Background: We investigated the impact of breast cancer molecular subtypes and treatment on survival in a cohort of medically insured women followed for more than 20 years.

Methods: We examined 934 female members of an integrated health care delivery system newly diagnosed with invasive breast cancer between 1988 and 1995 and followed them through 2008. Tumors were classified into four molecular subtypes on the basis of their expression profile: luminal A; luminal B; basal-like; and HER2-enriched. We followed women from the surgery date to death, health plan disenrollment, or study's end. HR and 95% confidence intervals (CI) were fit using Cox proportional hazards models adjusting for cancer treatments and tumor characteristics.

Results: A total of 223 (23.9%) women died because of breast cancer during the 21-year study period. Compared with women with luminal A tumors, women with HER2-enriched (HR 2.56, 95% CI 1.53–4.29) and luminal B tumors (HR 1.96, 95% CI: 1.08–3.54) had roughly a two-fold increased adjusted risk of breast cancer mortality. In addition, the survival curves suggest that risk of late mortality persists in women with luminal A tumors.

Conclusion: Among women with health care coverage, molecular subtypes were important predictors of breast cancer mortality. Women with HER2-enriched tumors and luminal B subtypes had the poorest survival despite adjusting for important covariates.

Impact: In a cohort followed for more than 20 years, women with HER2-enriched tumors had worse survival, but interestingly, the survival curve for women with luminal A tumors continued to steadily decline after 10 years of follow-up. *Cancer Epidemiol Biomarkers Prev*; 21(10); 1848–55. ©2012 AACR.

Introduction

Breast cancer will be responsible for nearly 39,510 deaths among women in 2012 in the United States (1). Breast cancer is a heterogeneous disease and several biologic subtypes have been identified (2). As conventional clinical factors such as tumor grade, size, lymph node involvement, and surgical margins are no longer sufficient as sole prognostic factors, it is important to consider breast cancer subtypes in treatment decision making. Limited knowledge exists if effectiveness of adjuvant treatment varies by subtype and how biologic subtypes affect long-term prognosis. Four main major breast cancer subtypes have been identified based on the

estrogen receptor (ER), progesterone receptor (PR), and HER2. These subtypes include luminal types A and B, basal-like and HER2-enriched (3). Luminal A is the most common breast cancer subtype and is characterized by ER⁺ and/or PR⁺/HER2⁻ status, low-grade tumors, and good prognosis (4–6). Luminal B subtype accounts for roughly 10% of all breast cancer and is distinguished by ER⁺ and/or PR⁺/HER2⁺ status. Breast cancer subtypes with negative ER, PR, and HER2 status are typically called "triple negative" breast cancers and approximate the basal-like category. The basal-like subtype is more common in premenopausal, younger, overweight, African American women and is associated with high-grade tumors (4, 6, 7). The HER2-enriched subtype (HER2⁺/ER⁻/PR⁻) is less common but is similarly characterized by high-grade tumors and poor outcomes (4, 5).

Most of the prior studies that examined survival by molecular subtypes lacked treatment data (2), and even fewer have examined long-term survival (8–12). Moreover, variations in laboratory methods have made it difficult to make meaningful conclusions. Therefore, the goal of the current study was to examine the impact of breast cancer subtypes and treatment on long-term survival considering important covariates. We conducted a

Authors' Affiliations: ¹Kaiser Permanente Southern California, Research & Evaluation, Pasadena, California; ²Department of Population Sciences, City of Hope, Duarte, California; ³Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California

Corresponding Author: Reina Haque, Kaiser Permanente Southern California, Department of Research & Evaluation, 100 South Los Robles Avenue, 2nd Floor, Pasadena, CA 91101. Phone: 011-626-564-5707; Fax: 011-626-564-3430; E-mail: Reina.Haque@kp.org

doi: 10.1158/1055-9965.EPI-12-0474

©2012 American Association for Cancer Research.

population-based cohort study of women diagnosed with invasive breast cancer who were members of a managed care organization in southern California and examined their survival over a 21-year period.

Materials and Methods

Patients and setting

The cohort included women diagnosed with invasive breast cancer (AJCC TNM stages I–IV) from January 1, 1988 to December 31, 1995 in a large integrated health care delivery system, Kaiser Permanente Southern California, San Diego (KPSC), and followed through December 31, 2008. We identified patients through the health plan's National Cancer Institute Surveillance Epidemiology and End Results-affiliated cancer registry. Eligible patients included those who completed their first course of treatment within the health plan. We identified a total of 1,645 women aged 25 to 79 years. We excluded 66 women who did not have medical charts, 96 women with missing information on cause of death, and 549 women with missing tumor tissue or ER/PR/HER2 status. The final cohort consisted of 934 women. The design of this study has been detailed previously (13).

Data elements

Data elements were ascertained from medical charts, the electronic cancer registry, and mortality databases. Date of death and cause (main outcome) were ascertained by linking our cohort with inpatient mortality files and California's master file of death certificates. Cause of death was confirmed by medical chart review. The main exposure variables included primary tumor treatment and biologic subtype. Treatment information of the primary tumor (type of surgery, chemotherapy dates, hormonal therapy, radiotherapy) was abstracted from medical records. Biologic subtypes were determined by immunohistochemical assays of ER, PR, and HER2 markers of archived formalin-fixed paraffin-embedded tumor tissue. The HER2/neu proto-oncogene was also assessed for gene amplification by FISH. The immunohistochemical and FISH assays were conducted at a single laboratory at the University of Southern California (USC) under the supervision of one of the authors (M.F. Press) according to methods previously described (14–17). Patients were classified into 4 main biologic subtypes based on previously published categories: luminal A (ER⁺ and/or PR⁺/HER2⁻), luminal B (ER⁺ and/or PR⁺/HER⁺), basal-like (ER⁻/PR⁻/HER⁻, "triple negative"), or HER2-enriched (HER2⁺/ER⁻/PR⁻; 2–3).

Covariates extracted from the patients' charts included demographic and health factors [age at diagnosis, year of diagnosis, race/ethnicity, family history of breast cancer in a first degree relative, menopausal status at diagnosis, body mass index (BMI) at diagnosis, history of tobacco use, and number of live births]. We also extracted tumor characteristics including grade, tumor–node–metastasis (TNM) stage, lymph node status, surgical margins, and histopathology. The Insti-

tutional Review Boards of KPSC and USC reviewed and approved the study.

Statistical analyses

Differences in demographic, health and tumor characteristics, and primary treatments by breast cancer subtype were first examined using χ^2 and Fisher exact tests. *P* values were 2 sided, and were considered significant if less than 0.05. We also examined mortality by breast cancer subtypes, stratified by stage at diagnosis. Follow-up commenced on the date of surgery (1988–1995) and ended on the date of death, termination of health plan membership, or study's end (December 31, 2008), whichever occurred first. Although some women disenrolled from the health plan, we were able to obtain their date and cause of death by linking their social security number with the state's electronic mortality files. HR and 95% confidence intervals (CI) were estimated fitting Cox proportional hazards models with time-dependent treatment variables (i.e., 0 up to start date; 1 after start date), and adjusted for stage and age at diagnosis, year of diagnosis, menopausal status, lymph node status, and treatment regimen. Kaplan–Meier methods were used to compare breast cancer and other cause mortality by subtype.

Results

Demographic and health characteristics of the 934 study participants are listed in Table 1. Study participants were followed a maximum of 21 years (median of 13.3 years, range 0.1–21.0 years), and had a median age of 59 years at diagnosis (range of 25 to 79 years). The most common breast cancer subtype was luminal A (66%), followed by basal-like (22%), HER2-enriched (7%), and luminal B (5%). The majority of women were white non-Hispanic (86%), and roughly one-third was diagnosed with breast cancer before the age of 50 years (32%). Race varied by biologic subtype. Although nonwhite women comprised less than 15% of the cohort, they were diagnosed with nearly one-quarter of all luminal B cancers and more than one-fifth of all HER2-enriched cancers. In the luminal B category, a larger proportion was premenopausal at diagnosis (52.5%) than postmenopausal (47.5%). There were no significant differences in BMI categories, history of tobacco use, family history of breast cancer in first degree relative, or number of live births by molecular subtype.

Table 2 displays the distribution of tumor characteristics by molecular subtype. Overall, the majority of study participants were diagnosed with early stage breast cancer (TNM stages I–II; 90%). Although numbers were small, a larger proportion of women with HER2-enriched tumors were diagnosed with late-stage disease (TNM III–IV, about 16.4%). Women with luminal B and HER2-enriched tumors were most likely to have positive lymph nodes. Compared with luminal A, women with luminal B, basal-like, and HER2-enriched subtypes were more likely to have higher grade tumors (*P* < 0.0001). Nearly all women (93% overall) had no residual tumor, and as expected, surgical margin status was not associated with

Table 1. Demographic and health characteristics of women at diagnosis by breast cancer subtype

	Luminal A (N = 615)	Luminal B (N = 42)	Basal-like (N = 210)	HER2-enriched (N = 67)	Total (N = 934)
	N (%)	N (%)	N (%)	N (%)	N (%)
Year of diagnosis					
1988–1989	90 (14.6)	4 (9.5)	34 (16.2)	9 (13.4)	137 (14.7)
1990–1991	124 (20.2)	12 (28.6)	39 (18.6)	10 (14.9)	185 (19.8)
1992–1993	191 (31.1)	16 (38.1)	68 (32.4)	18 (26.9)	293 (31.4)
1994–1995	210 (34.1)	10 (23.8)	69 (32.9)	30 (44.8)	319 (34.2)
<i>P</i> = 0.48					
Age at diagnosis (y)					
<50	163 (26.5)	24 (57.1)	81 (38.6)	26 (38.8)	294 (31.5)
50–59	120 (19.5)	6 (14.3)	54 (25.7)	18 (26.9)	198 (21.2)
60–69	187 (30.4)	11 (26.2)	47 (22.4)	18 (26.9)	263 (28.2)
>70	145 (23.6)	1 (2.4)	28 (13.3)	5 (7.5)	179 (19.2)
<i>P</i> < 0.0001					
Race					
White	540 (87.8)	32 (76.2)	177 (84.3)	53 (79.1)	802 (85.9)
Other	75 (12.2)	10 (23.8)	33 (15.7)	14 (20.9)	132 (14.1)
<i>P</i> = 0.044					
Family history of breast cancer^a					
Yes	110 (17.9)	9 (21.4)	33 (15.7)	9 (13.4)	161 (17.2)
No	416 (67.6)	29 (69.0)	148 (70.5)	50 (74.6)	643 (68.8)
Unknown	89 (14.5)	4 (9.5)	29 (13.8)	8 (11.9)	130 (13.9)
<i>P</i> = 0.62					
Menopausal status					
Pre	170 (31.3)	21 (52.5)	81 (44.0)	22 (37.9)	294 (35.6)
Post	373 (68.7)	19 (47.5)	103 (56.0)	36 (62.1)	531 (64.4)
<i>P</i> = 0.0017					
BMI (kg/m²)					
<18.5	8 (1.3)	1 (2.4)	4 (1.9)	2 (3.0)	15 (1.6)
18.5–24.9	213 (34.6)	14 (33.3)	74 (35.2)	15 (22.4)	316 (33.8)
25–29.9	172 (28.0)	14 (33.3)	62 (29.5)	28 (41.8)	276 (29.6)
≥30	140 (22.8)	8 (19.0)	43 (20.5)	13 (19.4)	204 (21.8)
Unknown	82 (13.3)	5 (11.9)	27 (12.9)	9 (13.4)	123 (13.2)
<i>P</i> = 0.42					
Smoking history					
Never	284 (46.2)	19 (45.2)	107 (51.0)	35 (52.2)	445 (47.6)
Smoker at diagnosis	94 (15.3)	8 (19.0)	21 (10.0)	7 (10.4)	130 (13.9)
Former smoker	134 (21.8)	8 (19.0)	53 (25.2)	14 (20.9)	209 (22.4)
Nonsmoker	36 (5.9)	4 (9.5)	8 (3.8)	4 (6.0)	52 (5.6)
Unknown	67 (10.9)	3 (7.1)	21 (10.0)	7 (10.4)	98 (10.5)
<i>P</i> = 0.43					
Live births					
0	78 (12.7)	7 (16.7)	32 (15.2)	11 (16.4)	128 (13.7)
≥1	464 (75.4)	32 (76.2)	148 (70.5)	49 (73.1)	693 (74.2)
Unknown	73 (11.9)	3 (7.1)	30 (14.3)	7 (10.4)	113 (12.1)
<i>P</i> = 0.63					

NOTE: *P* values based on χ^2 test. Unknown data were excluded in calculation of *P* value. For variables with categories <5, *P* values are based on the Fisher exact test.

^aHistory of breast cancer in first degree blood relative (mother, sister, or daughter).

subtype (*P* = 0.66). Roughly 8% (*n* = 78) of the cohort had invasive lobular carcinoma (ILC) histopathology and 5% (*n* = 49) had mixed histopathology. Histopathology was

related to molecular subtype; the fraction of women with IDC was highest in women with basal-like tumors and lowest in women with luminal A tumors, although the

Table 2. Tumor characteristics by breast cancer subtype

	Luminal A (N = 615)	Luminal B (N = 42)	Basal-like (N = 210)	HER2-enriched (N = 67)	Total (N = 934)
	N (%)	N (%)	N (%)	N (%)	N (%)
Grade					
1	98 (15.9)	0 (0)	8 (3.8)	0 (0)	106 (11.3)
2	460 (74.8)	23 (54.8)	83 (39.5)	28 (41.8)	594 (63.6)
3	54 (8.8)	19 (45.2)	118 (56.2)	38 (56.7)	229 (24.5)
Unknown	3 (0.5)	0 (0)	1 (0.5)	1 (1.5)	5 (0.5)
<i>P</i> < 0.0001					
TNM stage					
1	340 (55.3)	15 (35.7)	82 (39.0)	19 (28.4)	456 (48.8)
2	216 (35.1)	21 (50.0)	107 (51.0)	37 (55.2)	381 (40.8)
3	28 (4.6)	3 (7.1)	13 (6.2)	7 (10.4)	51 (5.5)
4	23 (3.7)	1 (2.4)	7 (3.3)	4 (6.0)	35 (3.7)
Unknown	8 (1.3)	2 (4.8)	1 (0.5)	0 (0)	11 (1.2)
<i>P</i> < 0.0001					
Lymph nodes					
Negative	374 (60.8)	20 (47.6)	128 (61.0)	28 (41.8)	550 (58.9)
Positive	207 (33.7)	18 (42.9)	71 (33.8)	33 (49.3)	329 (35.2)
Unknown	34 (5.5)	4 (9.5)	11 (5.2)	6 (9.0)	55 (5.9)
<i>P</i> = 0.019					
Surgical margins					
No residual tumor	570 (92.7)	39 (92.9)	193 (91.9)	63 (94.0)	865 (92.6)
Microscopic residual tumor	32 (5.2)	1 (2.4)	10 (4.8)	4 (6.0)	47 (5.0)
Margins not evaluable	3 (0.5)	1 (2.4)	3 (1.4)	0 (0)	7 (0.7)
No primary site surgery	4 (0.7)	1 (2.4)	2 (1.0)	0 (0)	7 (0.7)
Unknown	6 (1.0)	0 (0.0)	2 (1.0)	0 (0)	8 (0.9)
<i>P</i> = 0.66					
Histopathology					
IDC	521 (84.7)	37 (88.1)	192 (91.4)	57 (85.1)	807 (86.4)
ILC	61 (9.9)	2 (4.8)	12 (5.7)	3 (4.5)	78 (8.4)
Unknown/other	33 (5.4)	3 (7.1)	6 (2.9)	7 (10.4)	49 (5.2)
<i>P</i> = 0.056					

NOTE: *P* values based on χ^2 test. Unknown excluded in calculation of *P* value. For variables with categories <5, *P* values are based on the Fisher exact test.

Abbreviations: IDC, Invasive ductal carcinoma; ILC, Invasive lobular carcinoma.

fraction of women with ILC was highest in women with luminal A tumors and lowest in HER2-enriched tumors (*P* = 0.05).

Table 3 displays molecular subtype by treatment. Although all women in the cohort underwent surgery (mastectomy or breast conserving surgery) for primary treatment of the initial breast cancer diagnosis, use of adjuvant treatment varied across breast cancer subtype. Overall, tamoxifen was the most common adjuvant treatment (48%, *n* = 445), followed by chemotherapy (47%, *n* = 439) and radiotherapy (39%, *n* = 360). As expected, women with breast cancer subtypes that included ER⁺ or PR⁺ status (luminal A and luminal B) were more likely to use tamoxifen. Women with luminal B tumors were more likely to receive radiation (19.3%). Women with HER2-enriched tumors more often underwent chemotherapy (about 33%).

Table 4 presents the crude and adjusted HR for the association between breast cancer mortality and molecular subtype. Of the 934 women, 23.9% died because of breast cancer in the ensuing 21 years; 19.8% died because of other causes; 16.6% disenrolled from the health plan; and 39.7% completed follow-up (data not shown). Treatment groups were entered as indicator variables in the multivariable models. The multivariable model included age at diagnosis, year of first breast cancer diagnosis, menopausal status, lymph node status, and, for the "All stages" analysis, stage at diagnosis, as covariates. Breast cancer mortality was 2-fold greater in women with luminal B (HR 1.96, 95% CI: 1.08–3.54) and HER2-enriched tumors (HR 2.56, 95% CI: 1.53–4.29) as compared with women with the luminal A subtype (the referent group) when examining all stages combined. However, when examining the HRs stratified by stage, the association

Table 3. Receipt of treatment of initial breast cancer diagnosis in the cohort of 934 women by breast cancer molecular subtype

	Luminal A (N = 615)	Luminal B (N = 42)	Basal-like (N = 210)	HER2-enriched (N = 67)
	N (%)	N (%)	N (%)	N (%)
Treatment ^a				
Surgery	615 (42.4)	42 (38.5)	210 (44.7)	67 (44.9)
Radiation	252 (17.4)	21 (19.3)	69 (14.7)	18 (12.1)
Chemotherapy	231 (15.9)	23 (21.1)	136 (28.9)	49 (32.9)
Tamoxifen	352 (24.3)	23 (21.1)	55 (11.7)	15 (10.1)

^aColumn percentage exceed 100% due to multiple treatments.

between mortality and luminal B and HER2-enriched subtype was stronger among women with stage I disease [i.e., mortality was 7-fold higher in women with luminal B (HR 7.39, 95% CI: 1.72–31.77) and HER2-enriched (HR 6.62, 95% CI: 1.78–24.57) subtypes in comparison to women with luminal A tumors], but the CIs were wide. Although we found elevated mortality for basal-like tumors, the CI included the null (HR 1.20, 95% CI: 0.80–1.82 for all stages combined). The association for

basal-like tumors was similar when examining the effects by stage. Data were sparse in the higher stage categories (III–IV).

Figure 1 shows the Kaplan–Meier survival curves for breast cancer specific mortality. Women with luminal A tumors had the longest survival, although women with HER2-enriched and luminal B tumors had much shorter survival times ($P < 0.0001$). Women with basal-like tumors had intermediate survival times, with deaths occurring

Table 4. HRs for breast cancer mortality stratified by stage and major breast cancer subtypes (N = 934)


	Alive or Died of Other Causes	Died of Breast Cancer	Univariate HR (95% CI)	Adjusted HR^a (95% CI)
All stages				
Luminal A	490	128	1.00	1.00
Luminal B	25	15	2.01 (1.18–3.42)	1.96 (1.08–3.54)
Basal Like	157	52	1.30 (0.94–1.79)	1.20 (0.80–1.82)
HER2-enriched	41	26	2.39 (1.57–3.64)	2.56 (1.53–4.29)
Stage 1				
Luminal A	316	30	1.00	1.00
Luminal B	12	3	2.38 (0.73–7.81)	7.39 (1.72–31.77)
Basal Like	72	10	1.37 (0.67–2.79)	1.61 (0.54–4.81)
HER2-enriched	15	4	2.90 (1.02–8.26)	6.62 (1.78–24.57)
Stage 2				
Luminal A	156	65	1.00	1.00
Luminal B	12	9	1.84 (0.92–3.69)	2.23 (1.01–4.96)
Basal Like	78	29	1.06 (0.68–1.64)	1.22 (0.71–2.11)
HER2-enriched	25	12	1.26 (0.68–2.33)	1.85 (0.89–3.85)
Stage 3–4				
Luminal A	18	33	1.00	1.00
Luminal B	1	3	1.37 (0.42–4.48)	0.76 (0.17–3.39)
Basal Like	7	13	1.49 (0.78–2.84)	0.94 (0.31–2.86)
HER2-enriched	1	10	3.47 (1.68–7.19)	1.11 (0.25–4.89)

NOTE: 7 dichotomous variables were created to represent 8 breast cancer treatment categories:

(i) surgery+radiation+chemotherapy+tamoxifen; (ii) surgery+radiation+chemotherapy; (iii) surgery+radiation+tamoxifen; (iv) surgery+ chemotherapy+tamoxifen; (v) surgery+radiation; (vi) surgery+chemotherapy; (vii) surgery+ tamoxifen; (viii) surgery only.

^aHRs are adjusted for age at diagnosis, years of first breast cancer diagnosis, menopausal status, lymph node status, stage at diagnosis, and treatment regimens.

Figure 1. Kaplan–Meier survival curve for breast cancer mortality.



earlier than women with luminal A tumors. Survival declined precipitously during the first 3 to 4 years of follow-up for both HER2⁺ subtypes (HER2-enriched and luminal B), followed by a slowing in the decline over subsequent years of follow-up. The basal-like subtype showed a similar early decline over the first 2 to 2.5 years with a more gradual decline to about 13 years of follow-up. Interestingly, the curve for luminal A continues to decline steadily after 10 years of follow-up suggesting that the risk of late mortality persists in this group. As expected, Fig. 2 shows that breast cancer subtype had no impact on death because of all other causes of mortality ($P = 0.16$).

Discussion

In this cohort of nearly 1,000 women followed a maximum of 21 years, we determined that overall, women with HER2-enriched and luminal B tumors had a 2-fold increased adjusted risk of breast cancer mortality compared with women with luminal A tumors; these risks were seen after accounting for adjuvant treatments and other important covariates. These results are consistent with previous findings showing that women with HER2-enriched breast cancers have worse prognosis than those with luminal A tumors, although they were based on much shorter follow-up times (2). It is possible that aromatase inhibitors might have improved survival in this group; however, the drug was not available until the mid-2000s. It is also possible that the women with luminal B or HER2-enriched tumors died earlier than other patients because of unavailability of trastuzumab at that time, which was approved by the U.S. Food and Drug Admin-

istration for adjuvant treatment in 2005. The survival curve analysis (Fig. 1) also suggests that risk of late breast cancer-specific mortality persists women with luminal A tumors even after 10 years of follow-up. In addition, although previous studies focused on women with the more common basal-like subtype and reported poorer outcomes among those women compared with women with luminal A tumors, our study indicated reduced survival among women with luminal B and HER2-enriched tumors.

Our study has a number of strengths. As women for this study were identified through a large community-based health care delivery system in southern California, results may be more applicable to the wider community than studies which have drawn subjects from academic settings. In addition, the care the patients received should reflect the general cancer treatment patients received in other integrated delivery systems in the United States at that time. Unlike other studies that followed patients 5 to 10 years (2, 5), the managed care setting afforded a rare opportunity for very long-term follow-up of breast cancer patients. Health plan membership sustainment was high, with more than 4 of every 5 members continuing membership until either death or the end of the 21-year follow-up period. Furthermore, we minimized bias due to loss of follow-up by ascertaining mortality status of all patients, regardless of disenrollment status. Although others found reduced breast cancer survival due to poor health care access and lack of insurance coverage (18–23), we were able to examine differences in survival without the confounding effects of variable medical insurance coverage (24).




Figure 2. Kaplan–Meier survival curve for other causes of mortality.

Certain limitations of the study must also be considered. Although we mainly examined immunohistochemical markers, which may misclassify subtypes, the use of immunohistochemistry is more common in general community hospitals. Moreover, other studies have showed the concordance of the immunohistochemical and gene expression profiles to assess subtype (5, 8, 9). Another limitation was the lack of treatment data for recurrences. However, because the cohort consisted of a fully insured population with long-term membership sustainment, it is unlikely that survival rates by biologic subtype were highly dependent on treatment of recurrences. Because the cohort was assembled before the availability of trastuzumab and aromatase inhibitors, these results more closely reflect the natural history of the disease in the absence of these targeted therapies, but they may not be generalizable to current practices. However, given the high costs of trastuzumab (roughly \$100,000 per course) and aromatase inhibitors (up to \$5,000 per month), these therapies may not be accessible to all breast cancer survivors. Another challenge was the small cell sizes in some of the analyses because of low numbers of deaths. Also, as staging definitions were slightly different in the mid-1990s, it is possible that some of the cases would have actually been categorized as having a higher tumor-node-metastasis stage. In addition, the greater incidence of early stage disease in this insured cohort may be due to greater access to screening. Although we captured the types of cancer treatments, we did not have the data to quantify dose or duration.

In summary, our results extend the findings of prior studies given our long observation period. Although most survival studies are limited to 5 to 10 years of follow-up,

we followed cohort members for more than 20 years, revealing distinct changes in survival patterns by subtypes. Despite its markedly higher survival probabilities in earlier years of follow-up, luminal A subtype was the only subtype that continued a steady drop in survival over the 20-year period with little leveling off in later years. Future studies should examine how the association between molecular subtypes and survival varies by race/ethnicity, particularly in minority women who are more likely to have aggressive tumor subtypes, as well as identify factors to enhance survival in women with luminal A tumors.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Authors' Contributions

Conception and design: R. Haque, S.A. Ahmed, J.M. Shi, S.M. Enger, M.F. Press.

Development of methodology: R. Haque, S.A. Ahmed, J.M. Shi, S.M. Enger, M.F. Press.

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): R. Haque, C.C. Avila, S.M. Enger, M.F. Press.

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): R. Haque, J.M. Shi, C.C. Avila, J. Polikoff, L. Bernstein, S.M. Enger, M.F. Press.

Writing, review, and/or revision of the manuscript: R. Haque, S.A. Ahmed, G. Inzhakova, J.M. Shi, C.C. Avila, J. Polikoff, L. Bernstein, S.M. Enger, M.F. Press.

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): R. Haque, C.C. Avila, S.M. Enger, M.F. Press.

Study supervision: R. Haque, S.M. Enger, M.F. Press.

Acknowledgments

The authors would like to thank Angela Santiago, Roberta Guzman, and Ivonne Villalobos at USC for technical assistance with biomarker assays and data management.

Grant Support

The original cohort study was funded through the California Breast Cancer Research Program (S.M. Enger, M.F. Press). Additional work was supported by NIH/NCI R01CA136743 (R. Haque) and the Breast Cancer Research Foundation (M.F. Press).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked

advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received April 19, 2012; revised July 18, 2012; accepted July 22, 2012; published OnlineFirst September 18, 2012.

References

- American Cancer Society. Cancer Facts & Figures 2012. Atlanta: American Cancer Society; 2012.
- Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. *JAMA* 2006;295:2492–502.
- Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. *Nature* 2000;406:747–52.
- Perou CM, Borresen-Dale AL. Systems biology and genomics of breast cancer. *Cold Spring Harb Perspect Biol* 2011;3. pii: a003293.
- Blows FM, Driver KE, Schmidt MK, Broeks A, van Leeuwen FE, Wesseling J, et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. *PLoS Med* 2010;7:e1000279.
- Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. *Clin Cancer Res* 2007;13:2329–34.
- Millikan RC, Newman B, Tse CK, Moorman PG, Conway K, Dressler LG, et al. Epidemiology of basal-like breast cancer. *Breast Cancer Res Treat* 2008;109:123–39.
- Chang HR, Glaspy J, Allison MA, Kass FC, Elashoff R, Chung DU, et al. Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment. *Cancer* 2010;116:4227–37.
- Yerushalmi R, Hayes MM, Gelmon KA, Chia S, Bajdik C, Norris B, et al. A phase II trial of a neoadjuvant platinum regimen for locally advanced breast cancer: pathologic response, long-term follow-up, and correlation with biomarkers. *Clin Breast Cancer* 2009;9:166–72.
- Gabos Z, Thoms J, Ghosh S, Hanson J, Deschênes J, Sabri S, et al. The association between biological subtype and locoregional recurrence in newly diagnosed breast cancer. *Breast Cancer Res Treat* 2010;124:187–94.
- Santana-Davila R, Perez EA. Treatment options for patients with triple-negative breast cancer. *J Hematol Oncol* 2010;3:42.
- Dawood S. Triple-negative breast cancer: epidemiology and management options. *Drugs* 2010;70:2247–58.
- Enger SM, Greif JM, Polikoff J, Press M. Body weight correlates with mortality in early-stage breast cancer. *Arch Surg* 2004;139:954–58.
- Press MF, Slamon DJ, Flom KJ, Park J, Zhou J-Y, Bernstein L. Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. *J Clin Oncol* 2002;20:3095–105.
- Press MF, Spaulding B, Groshen S, Kaminsky D, Hagerty M, Sherman L, et al. Monoclonal antibodies designed for immunohistochemical detection of progesterone receptor in archival breast cancer specimens. *Steroids* 2002;67:799–813.
- Press MF, Sauter G, Bernstein L, Villalobos IE, Mirlacher M, Zhou JY, et al. Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. *Clin Cancer Res* 2005;11:6598–607.
- Press MF, Finn RS, Cameron D, Di Leo A, Geyer CE, Villalobos IE, et al. HER2 gene amplification, HER2 and EGFR messenger RNA and protein expression and lapatinib efficacy in women with metastatic breast cancer. *Clin Cancer Res* 2008;14:7861–70.
- Ihemelandu CU, Leffall LD Jr, Dewitty RL, Naab TJ, Mezghebe HM, Makambi KH, et al. Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: age-specific prevalence and survival. *J Surg Res* 2007;143:109–18.
- Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. *Proc Natl Acad Sci U S A* 2001;98:10869–74.
- Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. *Proc Natl Acad Sci U S A* 2003;100:8418–23.
- Shavers VL, Brown ML. Racial and ethnic disparities in the receipt of cancer treatment. *J Natl Cancer Inst* 2002;94:334–57.
- Schneider EC, Zaslavsky AM, Epstein AM. Racial disparities in the quality of care for enrollees in Medicare managed care. *JAMA* 2002;287:1288–94.
- Sparano JA, Wang M, Zhao F, Stearns V, Martino S, Ligibel JA, et al. Race and hormone receptor positive breast cancer outcomes in a randomized chemotherapy trial. *J Natl Cancer Inst* 2012;104:406–14.
- Haque R, Achacoso NS, Fletcher SW, Nekhlyudov L, Collins LC, Schnitt SJ, et al. Treatment of ductal carcinoma *in situ* among patients cared for in large integrated health plans. *Am J Manag Care* 2010;16:351–60.